GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (STU:7W3) » Definitions » Tax Expense

Acotec Scientific Holdings (STU:7W3) Tax Expense : €-0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings Tax Expense?

Acotec Scientific Holdings's tax expense for the months ended in Jun. 2024 was €-0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.00 Mil.


Acotec Scientific Holdings Tax Expense Historical Data

The historical data trend for Acotec Scientific Holdings's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acotec Scientific Holdings Tax Expense Chart

Acotec Scientific Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
0.46 1.62 1.64 0.02 -

Acotec Scientific Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 - - - -

Acotec Scientific Holdings Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acotec Scientific Holdings  (STU:7W3) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Acotec Scientific Holdings Tax Expense Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Acotec Scientific Holdings Business Description

Traded in Other Exchanges
Address
16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN
Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.

Acotec Scientific Holdings Headlines

No Headlines